文献速递MDS 与骨髓增殖性肿瘤白血病

JAK2与ERK双靶向干预干扰骨髓增殖性肿瘤克隆并增强疗效

Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy.
PubMed 文献 · Leukemia · 2021-09-03

研究在Jak2V617F骨髓增殖性肿瘤(MPN)小鼠、细胞及患者临床分离标本中,采用遗传学和药理学手段靶向ERK1/2。结果显示,ERK1/2缺失可减轻MPN特征并减少Jak2V617F克隆;芦可替尼联合ERK抑制剂可抑制细胞增殖、纠正红细胞增多和脾大,长期治疗可诱导克隆减少并显著减轻骨髓纤维化。

要点

  • ERK1/2缺失可减少Jak2V617F克隆并减轻MPN特征
  • 芦可替尼联合ERK抑制剂可纠正小鼠红细胞增多和脾大
  • 联合抑制对PV、ET、MF患者CD34+细胞集落形成呈剂量依赖性抑制

核心结论

  • JAK2与ERK1/2双靶向可增强MPN克隆控制和治疗疗效,提示为MPN的新治疗策略。

研究设计与样本

  • 在Jak2V617F MPN小鼠、细胞及患者临床分离标本中开展遗传学和药理学ERK1/2靶向研究。
  • 进行Jak2V617F与野生型骨髓竞争移植,比较造血系统ERK1/2缺失的影响。
  • 药理研究采用芦可替尼联合ERK抑制剂,并评估MPLW515L驱动MPN的骨髓纤维化。

主要发现

  • 竞争移植显示造血系统ERK1/2缺失减轻MPN特征,并减少血液和造血祖细胞区室中的Jak2V617F克隆。
  • ERK1/2缺失联合JAK2抑制抑制MAPK转录程序、使血细胞计数正常化并促进克隆控制。
  • 芦可替尼联合ERK抑制剂减少Jak2V617F细胞增殖,纠正Jak2V617F MPN小鼠的红细胞增多和脾大。
  • 较长疗程联合治疗可诱导克隆减少。
  • MPLW515L驱动MPN的骨髓纤维化在联合治疗下显著减轻,程度未见JAK2抑制剂单药治疗达到。

临床怎么用

  • 对JAK2V617F阳性MPN,JAK2抑制剂基础上联合ERK1/2抑制可能增强克隆控制并改善脾大、红细胞增多及骨髓纤维化。
  • PV、ET、MF患者CD34+细胞对联合JAK2/ERK1/2抑制敏感,支持在该类患者中探索联合方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myeloproliferative neoplasms (MPN) show dysregulated JAK2 signaling. JAK2 inhibitors provide clinical benefits, but compensatory activation of MAPK pathway signaling impedes efficacy. We hypothesized that dual targeting of JAK2 and ERK1/2 could enhance clone control and therapeutic efficacy. We employed genetic and pharmacologic targeting of ERK1/2 in Jak2V617F MPN mice, cells and patient clinical isolates. Competitive transplantations of Jak2V617F vs. wild-type bone marrow (BM) showed that ERK1/2 deficiency in hematopoiesis mitigated MPN features and reduced the Jak2V617F clone in blood and hematopoietic progenitor compartments. ERK1/2 ablation combined with JAK2 inhibition suppressed MAPK transcriptional programs, normalized cytoses and promoted clone control suggesting dual JAK2/ERK1/2 targeting as enhanced corrective approach. Combined pharmacologic JAK2/ERK1/2 inhibition with ruxolitinib and ERK inhibitors reduced proliferation of Jak2V617F cells and corrected erythrocytosis and splenomegaly of Jak2V617F MPN mice. Longer-term treatment was able to induce clone reductions. BM fibrosis was significantly decreased in MPLW515L-driven MPN to an extent not seen with JAK2 inhibitor monotherapy. Colony formation from JAK2V617F patients' CD34+ blood and BM was dose-dependently inhibited by combined JAK2/ERK1/2 inhibition in PV, ET, and MF subsets. Overall, we observed that dual targeting of JAK2 and ERK1/2 was able to enhance therapeutic efficacy suggesting a novel treatment approach for MPN.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Brkic S, Stivala S, Santopolo A, et al. Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy. Leukemia. 2021. PMID: 34480104. doi:10.1038/s41375-021-01391-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。